Table III.
Topical anti-VEGF agent concentrations of various studies
| Anti-VEGF Agent | Concentration | Dose | Model | Author |
|---|---|---|---|---|
| Aflibercept Aflibercept Bevacizumab |
4 mg/ml 0.4 mg/ml 2.5 mg/ml |
Not specified | Rabbit | Park 2015 (46) |
| Bevacizumab | 2.5 mg/ml | 2X/day | Human | Krizova 2014 (47) |
| Bevacizumab | 10 mg/ml | 2X/day | Rat | Ozdemir 2014 (48) |
| Bevacizumab | 6 mg/ml 25 mg/ml |
2X/day | Rabbit | Kadar 2014 (49) |
| Ranibizumab | 10 mg/ml | 4X/day | Human | Ferrari 2013 (50) |
| FITC labeled Bevacizumab | 2.67 mg/ml | 0.534 mg (0.2 ml, 2.67 mg/ml) | Franz cell | Pescina 2010 (27) |
| Bevacizumab | 12.5 mg/ml | 3X/day | Rabbit | Ahmed 2009 (51) |
| Bevacizumab | 10 mg/ml | 2X/day 4X/day |
Human | Dastjerdi 2009 (52) |
| Bevacizumab | 5 mg/ml | Eye drops, 5X/day | Human | Koenig 2009 (53) |
| Bevacizumab | 5 mg/ml | 5X/day | Human | Bock 2008 (54) |
| Bevacizumab | 12.5/ml | 2X/day | Human | Kim 2008 (55) |
| Bevacizumab | 10 mg/ml | 4X/day | Human | DeStafeno 2007 (56) |